RTW Investments LP boosted its stake in LivaNova PLC (NASDAQ:LIVN) by 207.9% during the 2nd quarter, HoldingsChannel reports. The fund owned 431,000 shares of the company’s stock after buying an additional 291,000 shares during the period. LivaNova comprises 3.1% of RTW Investments LP’s portfolio, making the stock its 8th largest position. RTW Investments LP’s holdings in LivaNova were worth $43,022,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its holdings in shares of LivaNova by 1,054.2% during the second quarter. Envestnet Asset Management Inc. now owns 1,662 shares of the company’s stock worth $166,000 after purchasing an additional 1,518 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of LivaNova during the first quarter worth $174,000. Gideon Capital Advisors Inc. acquired a new stake in shares of LivaNova during the second quarter worth $218,000. Oakbrook Investments LLC acquired a new stake in shares of LivaNova during the second quarter worth $334,000. Finally, Matarin Capital Management LLC acquired a new stake in shares of LivaNova during the first quarter worth $376,000. 86.92% of the stock is currently owned by hedge funds and other institutional investors.
LIVN stock opened at $124.19 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.08 and a current ratio of 1.51. LivaNova PLC has a fifty-two week low of $62.67 and a fifty-two week high of $127.85. The stock has a market capitalization of $6.04 billion, a P/E ratio of 37.31, a PEG ratio of 3.58 and a beta of 0.93.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, August 1st. The company reported $0.96 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.04. LivaNova had a negative net margin of 4.93% and a positive return on equity of 9.24%. The business had revenue of $287.50 million for the quarter, compared to analysts’ expectations of $278.08 million. During the same quarter last year, the company earned $0.93 EPS. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. research analysts forecast that LivaNova PLC will post 3.24 earnings per share for the current fiscal year.
In related news, insider David S. Wise sold 1,500 shares of the stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $104.46, for a total value of $156,690.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Douglas John Manko sold 2,058 shares of the stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $121.61, for a total transaction of $250,273.38. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,058 shares of company stock worth $888,223. Corporate insiders own 0.41% of the company’s stock.
A number of brokerages have weighed in on LIVN. ValuEngine raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 27th. Needham & Company LLC reissued a “buy” rating and set a $135.00 target price (up from $128.00) on shares of LivaNova in a report on Wednesday, August 1st. BidaskClub cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 12th. Zacks Investment Research raised shares of LivaNova from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. Finally, Stifel Nicolaus began coverage on shares of LivaNova in a report on Friday, June 8th. They set a “buy” rating and a $115.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $102.67.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Story: Google Finance Portfolio Tips and Tricks
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.